Orforglipron: difference between revisions
Diff·revision 10 → 11·17:50, 14 Apr 2025
Difference between revision 10 and revision 11 of Orforglipron. 2 lines changed; the page grew by 300 bytes.
| Revision 10 — 13:23, 25 Mar 2025 Chromatokid (talk) expand §Reported clinical findings 4,165 bytes +109 | Revision 11 — 17:50, 14 Apr 2025 TimelineTiernan (talk) split §Pharmacology into receptor binding and downstream signalling 4,465 bytes +300 | ||
|---|---|---|---|
| 33 | Gastrointestinal adverse events were dose-related and qualitatively similar to those of injected agonists, which argues that they are a receptor-level rather than a route-level phenomenon.{{r|frias2023orfo,drucker2018}} | 33 | Gastrointestinal adverse events were dose-related and qualitatively similar to those of injected agonists, which argues that they are a receptor-level rather than a route-level phenomenon.{{r|frias2023orfo,drucker2018}} |
| 34 | 34 | ||
| + | 35 | Because the compound is not a peptide, it is subject to cytochrome-mediated metabolism and to the drug-interaction considerations that entails — a difference from the peptide agonists, which have essentially no cytochrome-mediated interactions. Interaction data are part of the phase 3 programme. | |
| + | 36 | ||
| 35 | == References == | 37 | == References == |
| 36 | {{reflist}} | 38 | {{reflist}} |